Question 1

What are the early visual symptoms of Bietti crystalline dystrophy, and how do they progress over time?

Accepted Answer

Early symptoms often include night blindness (nyctalopia) and the presence of small, yellow or white crystal-like deposits in the retina, which may be visible during an eye exam but not necessarily noticeable to the patient initially. As the condition progresses, these lipid deposits accumulate and damage the retinal tissue, leading to a gradual narrowing of the peripheral vision (tunnel vision) and eventual central vision loss. The progression is typically slow, occurring over decades, but it is irreversible.

Question 2

How do CYP4V2 gene variations affect the risk of deep venous thrombosis, and who should be tested?

Accepted Answer

Certain common variations, or polymorphisms, in the CYP4V2 gene have been associated with an increased risk of deep venous thrombosis (DVT). While the exact mechanism linking this fatty acid oxidation enzyme to blood clotting is not fully understood, individuals with these variants may have a higher predisposition to clot formation. Testing is generally not recommended for the general population but may be considered for individuals with a personal or family history of unexplained blood clots, particularly if other common clotting disorders have been ruled out.

Question 3

Does a diagnosis of Bietti crystalline dystrophy increase the risk of other health conditions beyond vision loss?

Accepted Answer

While Bietti crystalline dystrophy is primarily an eye disorder, the CYP4V2 gene is involved in fatty acid oxidation, which is a fundamental metabolic process. Some studies suggest a potential link between CYP4V2 variants and an increased risk of deep venous thrombosis. However, the primary clinical focus for patients with Bietti crystalline dystrophy remains on monitoring retinal health and managing vision loss. Patients should discuss their overall cardiovascular and clotting risk with their healthcare provider, especially if they have a family history of thrombotic events.

Question 4

Is there a cure for Bietti crystalline dystrophy, and what treatments can help manage vision loss?

Accepted Answer

Currently, there is no cure for Bietti crystalline dystrophy, as the underlying genetic mutation in the CYP4V2 gene cannot be reversed. Treatment focuses on managing symptoms and preserving remaining vision. This may include low-vision aids, such as magnifiers or telescopic lenses, and occupational therapy to help patients adapt to visual impairment. Research into gene therapy is ongoing, but no approved genetic treatments are available yet.

CYP4V2 gene

Normal Function

Health Conditions Related to Genetic Changes

Bietti crystalline dystrophy

Other disorders

Other Names for This Gene

Frequently Asked Questions